These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 24618930)

  • 1. Interleukin 1β: a proinflammatory target for preventing atherosclerotic heart disease.
    McCarty S; Frishman W
    Cardiol Rev; 2014; 22(4):176-81. PubMed ID: 24618930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Thuren T; Zalewski A; Libby P
    Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes.
    Everett BM; Donath MY; Pradhan AD; Thuren T; Pais P; Nicolau JC; Glynn RJ; Libby P; Ridker PM
    J Am Coll Cardiol; 2018 May; 71(21):2392-2401. PubMed ID: 29544870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of interleukin 1β inhibition in cardiovascular disease.
    Qamar A; Rader DJ
    Curr Opin Lipidol; 2012 Dec; 23(6):548-53. PubMed ID: 23069985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis.
    Ridker PM
    Circ Res; 2019 Feb; 124(3):437-450. PubMed ID: 30702995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
    Ridker PM
    Trans Am Clin Climatol Assoc; 2013; 124():174-90. PubMed ID: 23874021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Examining the Role of and Treatment Directed at IL-1β in Atherosclerosis.
    Khan R; Rheaume E; Tardif JC
    Curr Atheroscler Rep; 2018 Sep; 20(11):53. PubMed ID: 30219977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [CAPS treatment].
    Jiménez Treviño S; Ramos Polo E
    Med Clin (Barc); 2011 Jan; 136 Suppl 1():29-33. PubMed ID: 21596184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The inflammasome and IL-1β: implications for the treatment of inflammatory diseases.
    Satoh T; Otsuka A; Contassot E; French LE
    Immunotherapy; 2015; 7(3):243-54. PubMed ID: 25804477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.
    Church LD; McDermott MF
    Expert Rev Clin Immunol; 2010 Nov; 6(6):831-41. PubMed ID: 20979548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Libby P; MacFadyen JG; Thuren T; Ballantyne C; Fonseca F; Koenig W; Shimokawa H; Everett BM; Glynn RJ
    Eur Heart J; 2018 Oct; 39(38):3499-3507. PubMed ID: 30165610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-ischaemic administration of the murine Canakinumab-surrogate antibody improves outcome in experimental stroke.
    Liberale L; Diaz-Cañestro C; Bonetti NR; Paneni F; Akhmedov A; Beer JH; Montecucco F; Lüscher TF; Camici GG
    Eur Heart J; 2018 Oct; 39(38):3511-3517. PubMed ID: 29788103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atherosclerosis: perspectives of anti-inflammatory therapy.
    Nasonov EL; Popkova TV
    Ter Arkh; 2018 May; 90(5):4-12. PubMed ID: 30701884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders.
    Church LD; McDermott MF
    Curr Opin Mol Ther; 2009 Feb; 11(1):81-9. PubMed ID: 19169963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical characterization and clinical development of ILARIS(®) (canakinumab) for the treatment of autoinflammatory diseases.
    Gram H
    Curr Opin Chem Biol; 2016 Jun; 32():1-9. PubMed ID: 26720283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases.
    Emmi G; Urban ML; Imazio M; Gattorno M; Maestroni S; Lopalco G; Cantarini L; Prisco D; Brucato A
    Curr Cardiol Rep; 2018 Jun; 20(8):61. PubMed ID: 29904899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canakinumab for secondary prevention of atherosclerotic disease.
    Capodanno D; Angiolillo DJ
    Expert Opin Biol Ther; 2018 Feb; 18(2):215-220. PubMed ID: 29265905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.
    Koenig W
    Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Interleukin-1 in the Treatment of Selected Cardiovascular Complications.
    Heydari FS; Zare S; Roohbakhsh A
    Curr Rev Clin Exp Pharmacol; 2021; 16(3):219-227. PubMed ID: 32674739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis.
    Ridker PM; MacFadyen JG; Thuren T; Libby P
    Eur Heart J; 2020 Jun; 41(23):2153-2163. PubMed ID: 31504417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.